Thomas Flaig, MD

Flaig TW, Su Lih-Jen, Agarwal R, Glode LM. Silibin synergizes with mitoxantrone to inhibit cell growth via apoptosis in prostate cancer cells. (In press: International Journal of Cancer)

Arthur C, Flaig T, Su L, Denney R, Barnes F, Glode LM. The effect of ultrasonic irradiation on adriamycin-induced cytotoxicity in three human bladder cancer cell lines. (Accepted: Ultrasonics)

Saba N, Flaig T, Rausch D, Belzer M. Topoisomerase II Inhibitor Induced Leukemia in a Patient with AIDS. AIDS. 2001; 15(3): 421-423. [Research Letter]

Glode LM, Pierson AS, Barqawi AB, Flaig T. Prostate Cancer Diagnosis, Risk Assessment and Management (2 hours of AMA CME). On-line publication: January 19, 2005 (3rd version). www.vlh.com (The Virtual Lecture Hall).

Flaig TW, Crighton F. Prostate Cancer in Oncology Nursing Secrets. Gates RA, Fink RM (eds). Hanley and Belfus, Philadelphia, PA, 2007.

Agarwal R, Su L-J, Flaig T, Harrison GS, Gustafson D, and Glode LM: A phase I clinical study of silibinin in patients with prostate cancer. Prostate Cancer Foundation, October 2004.

Flaig T, Barqawi AB, Kane M, Miller G, Crawford ED , and Glode LM: A Phase II trial of dexamethasone, 1,25-dihydroxyvitamin D and Carboplatin in patients with hormone refractory prostate cancer. ASCO/ASTRO/PCF/SUO Prostate Symposium (Orlando, FL) February 2005 (abstract #302).

Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park). 2013 Sep;27(9):893, 896, 898. PubMed PMID: 24282987

Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9. PubMed PMID: 24080993

Yang X, La Rosa FG, Genova EE, Huber K, Schaack J, Degregori J, Serkova NJ, Li Y, Su LJ, Kessler E, Flaig TW. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One. 2013;8(9):e74809. PubMed PMID: 24058630

Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson Drph JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Yann Tsai W, Wu DP, Lee V, Greenlee H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther. 2014 Jan;13(1):46-53. PubMed PMID: 23757319

Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May;49(5):303-15. PubMed PMID: 23724410

Verdoorn BP, Kessler ER, Flaig TW. Targeted therapy in advanced urothelial carcinoma. Oncology (Williston Park). 2013 Mar;27(3):219-26. PubMed PMID: 23687793

Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Dermatol Surg. 2013 Jul;39(7):981-7. PubMed PMID: 23464361

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. PubMed PMID: 23228172

Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol. 2013 Jan;10(1):41-51. PubMed PMID: 23183631

Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 2013 Jan 1;19(1):148-57. PubMed PMID: 23172881

Flaig T, Agarwal R, Su L, Harrison GS, Gustafson D, and Glode LM: A Phase I study of silibinin in hormone refractory prostate cancer. Journal of Clinical Oncology 23:427s, 2005 (suppl, abstract #4698).

Flaig TW, Su L, Harrison G, Agarwal R, and Glode LM. Silibinin synergizes with mitoxantrone to decrease cell viability in prostate cancer cells. ASCO/ASTRO/PCF/SUO prostate symposium - San Francisco, CA - February 26, 2006 (abstract #354).

Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb;31(1):115-25. PubMed PMID: 22415798

Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urol Oncol. 2013 Oct;31(7):968-73. PubMed PMID: 22300756

Clemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol. 2013 Feb;31(2):198-204. PubMed PMID: 21795073

Flaig TW, Su L, Shade T, Harrison G, Glod3 LM. Gene expression changes with silibinin and mitoxantrone treatment in prostate cancer cells. AACR Innovations in Prostate Cancer Research, San Francisco, CA December 8, 2006.

Buesing JR, Su L, Raben D, Glodi LM, and Flaig TW. The cooperative effects of silibinin, an agent with activity against growth factor signaling in combination with ionizing radiation against human bladder cancer. Western Student Medical Research Forum - Carmel, California. February 2, 2007.

Bourlon MT, Amini A, Kavanagh BD, Flaig TW. Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapy. Oncology (Williston Park). 2014 Nov 7;28(11). PubMed PMID: 25560737

Bourlon MT, Flaig TW. Visceral metastases in prostate cancer: an underestimated and understudied subgroup. Oncology (Williston Park). 2014 Nov 7;28(11). PubMed PMID: 25403630

Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2014 Aug 20. [Epub ahead of print] PubMed PMID: 25151595

Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep;37(7):360-5. PubMed PMID: 25075565

Flaig TW, Breaker K, Crighton F, Schultz M, Costa L, Kim F, and Drabkin H. The combination of Tarceva and Rapamune in the treatment of advanced renal cell carcinoma – interim safety and tolerability assessment. The Sixth International Kidney Cancer Symposium. Chicago, IL. October 12, 2007.

Rusthoven K, Flaig T, Raben D, and Kavanagh B. High incidence of lung cancer after non-muscle invasive transitional cell carcinoma of the bladder: Implications for screening trials. 2008 Genitourinary cancers symposium. San Francisco, CA. February 15, 2008 (Abstract #296)

Flaig TW, Su L, McCoach C, Harrison GS, Varella-Garcia Marileila, Bemis LT. Dual EGFR and VEGFR inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose and sequence dependent manner. 2008 Genitourinary cancers symposium. San Francisco, CA. February 15, 2008 (Abstract #331).

Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2014 Jul 24. [Epub ahead of print] PubMed PMID: 25065704

LaRosa FG, Flaig TW, Wilson S, Crawford ED, and Kim FJ. Sarcoidosis in a man with renal carcinoid tumor. Oncology, 2007; 21(13): 1593-1596.

Flaig TW, Tangen CM, Hussain M, Stadler WM, Raghavan D, Crawford ED and Glodé LM. Randomization reveals unexpected acute leukemias in SWOG prostate cancer trial. (Accepted to the Journal of Clinical Oncology - anticipated March of 2008).

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014 Sep 1;32(25):2765-72. PubMed PMID: 25049330

Flaig TW, Tangen CM, Hussain M, Stadler WM, Raghavan D, Crawford ED and Glodé LM. Randomization reveals unexpected acute leukemias in SWOG prostate cancer trial. Journal of Clinical Oncology. 2008 26(9):1532-6.

Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug;32(6):826-32. PubMed PMID: 24931270

Kessler ER, Flaig TW. Geriatric considerations in the treatment of advanced prostate cancer. F1000Prime Rep. 2014;6:33. PubMed PMID: 24860655

Cost NG, Maroni P, Flaig TW. Metastatic relapse after initial clinical stage I testicular Leydig cell tumor. Oncology (Williston Park). 2014 Mar;28(3):211, 214. PubMed PMID: 24855728

Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Tsai WY, Wu DP, Lee V, Greenlee H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther. 2014 Jan;13(1):46-53. PubMed PMID: 23757319

Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9. PubMed PMID: 24080993

Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014 Jul;32(5):707-13. PubMed PMID: 24629494

Rusthoven KE, Flaig TW, Raben D and Kavanagh B. High Incidence of Lung Cancer after Non-Muscle-Invasive Transitional Cell Carcinoma of the Bladder: Implications for Screening Trials. Clinical Lung Cancer. 2008; 9(2): 106-111.

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Eur Urol. 2014 Mar 6. [Epub ahead of print] PubMed PMID: 24647231

Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC. Geriatric oncology for the 21st century: a call for action. J Oncol Pract. 2014 Jul;10(4):241-3. PubMed PMID: 24781365

Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J Biomed Nanotechnol. 2014 Jul;10(7):1267-76. PubMed PMID: 24804547

O’Bryant CL, Flaig TW and Utz KL. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy. 2008; 28(8):1071-5.

Flaig, TW and Glodé, LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother 2008 9(16):2829-41.

Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH Jr, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014;2:2. PubMed PMID: 24829759

Dean F. Bajorin, Padmanee Sharma, Leonard G. Gomella, Elizabeth R. Plimack, Peter H. O'Donnell, Jean H. Hoffman-Censits, Thomas W. Flaig, David I. Quinn, Robert Brownell Sims, Michael Locker, Nadeem A. Sheikh, Todd DeVries, Seth P. Lerner. NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer. J Clin Oncol 32, 2014 (suppl 4; abstr 296^)

Thomas W. Flaig, Ravi C. Potluri, Yvette Ng, Mary Beth Todd, Maneesha Mehra. Treatment evolution for metastatic castration-resistant prostate cancer (mCRPC) with recent introduction of new oral agents: Retrospective analysis of real world data. J Clin Oncol 32, 2014 (suppl; abstr e16010)

Evan Y. Yu, Robert H. Getzenberg, Jordan Smith, Michael L. Hancock, Ronald Tutrone, Thomas W. Flaig, James T. Dalton, Mitchell S. Steiner, Karl R Westenfelder, Miklos Szucs. The effect of low-dose GTx-758 on free testerone levels in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 32, 2014 (suppl 4; abstr 60)

Karim Fizazi, Thomas W. Flaig, Carsten-Henning Ohlmann, Howard I. Scher, Johann Sebastian De Bono, Dana E. Rathkopf, Charles J. Ryan, Thian San Kheoh, Jinhui Li, Mary Beth Todd, Thomas W. Griffin, Arturo Molina, Michael Stöckle. Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials. J Clin Oncol 32, 2014 (suppl 4; abstr 20)

Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2015 Dec 29. [Epub ahead of print] PubMed PMID: 26710718

Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 Dec;29(12). PubMed PMID: 26676900

Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2015 Nov 25. [Epub ahead of print] PubMed PMID: 26609008

Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016 Feb;27(2):286-94. PubMed PMID: 26578735

Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28;10:218. PubMed PMID: 26510665

Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA. Silibinin suppresses cd44 expression in prostate cancer cells. Am J Transl Res. 2009; 1(1): 80-87

Flaig TW, Kim FJ, LaRosa FG, Schoen J, and Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investigational New Drugs. 2009; 27(1): 83-7.

Flaig TW, Su L, Uhlik C, Li Y, Raben D, Garcia M, and Bemis L Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Feb 10 [epub ahead of print] PMID 19220256.

Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e589-96. PubMed PMID: 26142027

Bourlon MT, Flaig TW. The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma. Curr Drug Targets. 2016;17(2):196-205. PubMed PMID: 26044568

Flaig TW and Crighton F. Prostate Cancer. In Oncology Nursing Secrets, Third edition. Gates RA and Fink RM (eds). Mosby Elsevier, Saint Louis, pp 323-335, 2008.

Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA 3rd. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015 Apr;12(4):225-35. PubMed PMID: 25800393

Barqawi AB, Flaig TW. Testis Cancer. British Medical Journal Publishing Group, point-of-care web site. (e-published: epocrates.com) Aug 2008 (This submission was peer-reviewed)

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. PubMed PMID: 25601341

Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2015 Feb;33(2):71.e11-9. PubMed PMID: 25151595

Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb;33(2):53-64. PubMed PMID: 25065704

Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S. A man with changes in the urinary bladder: Benign metaplasia or adenocarcinoma. Oncology, 2009; 23(2): 177-80.

Flaig T, Curti B, Gordon M, VanVeldhuizen P, Miller W, Ernstoff M, Bhatia S, Hunder N, Royer N, and Thompson J. Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study. 20th EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics” Geneva, Switzerland. October 21-24, 2008

Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database. Clin Genitourin Cancer. 2016 Oct 18. [Epub ahead of print] PubMed PMID: 27876504

Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. Urology. 2016 Oct 18. [Epub ahead of print] PubMed PMID: 27769917

Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 Dec;5(12):3386-3393. PubMed PMID: 27758076

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224. PubMed PMID: 27697976

de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PF, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2016 Jul 8. [Epub ahead of print] PubMed PMID: 27402060

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 Aug 20;34(24):2835-42. PubMed PMID: 27325855

Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016 Feb;5(2):182-91. PubMed PMID: 26710718

Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016 Apr;27(4):699-705. PubMed PMID: 26609008

Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016 Feb;27(2):286-94. PubMed PMID: 26578735

Flaig TW, Costa L, Breaker K, Schultz M, Crighton F, Kim FJ , Drabkin HA. Erlotinib with sirolimus for advanced renal cell carcinoma: Preliminary efficacy results. 2009 Genitourinary cancer symposium. Orlando, FL. (2-30-09).

Bourlon MT, Flaig TW. The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma. Curr Drug Targets. 2016;17(2):196-205. PubMed PMID: 26044568

Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su L, Yuan L, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A Study of High-Dose Oral Silybin-Phytosome Followed by Prostatectomy in Patients with Localized Prostate Cancer. The Prostate 2010 Feb 1. [Epub ahead of print] PMID: 20127732

Flaig, TW J Urol. 2009; 181(5): 2007. [editorial comments]

Siomos VF, La Rossa FG, Flaig TW, Kondo KI, Mitchell JD, Wilson S, Barqawi AB. Recurrent urothelial carcinoma with pulmonary metastasis. Oncology, 2009; 23(14): 1301-4

Yang, X and Flaig, TW. Novel Targeted Agents for the Treatment of Bladder Cancer: Translating Laboratory Advances into Clinical Application (in press: International Brazilian Journal of Urology)

Clemons J, Glodé LM, Flaig T. Low dose diethylstilbestrol for the treatment of advanced prostate cancer. AACR 100th Annual Meeting 2009 in Denver, CO - April 21, 2009

Flaig TW, Glode LM, Gustafson D, Van Bokhoven A, Tao Y, Wilson S, Su L, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MD, Pollak M. A pilot study of oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. AACR 100th Annual Meeting 2009 in Denver, CO - April 21, 2009

Li Y, Su L, Yang X, Flaig T. The synergistic activity of VEGFR inhibition via pazopanib plus docetaxel in bladder cancer cells. AACR 100th Annual Meeting 2009 in Denver, CO - April 21, 2009

French K, Su L, Yang X, Flaig T. The Role of Beta Tubulin 3 in Bladder Cancer Resistance to Taxane Treatment. 2009 UCCC Student Cancer Research Fellowship Program – August 6, 2009

Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, and Glodé LM. Adjuvant androgen deprivation for high risk prostate cancer after radical prostatectomy: Southwest oncology group (SWOG) Study S9921. Journal of Clinical Oncology 2011; 29(15): 2040-5. PMID 21502546.

Li Y, Yang X, Su L, Flaig, TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 2011;78(1): 233.e7—233.e13. PMID 21529900 PMC3126899

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, KKheoh T, Haqq CM, Scher HI. Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine 2011; 364(21): 1995-2005.

Clemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urologic Oncology 2011 JUL 25 [epub ahead of publication] PMID 21795073

Flaig TW, Wilson S, van Bokhoven A, Varella-Garcia M, Wolfe P, Maroni P, Genova EE, Morales D, Lucia MS. The detection of circulation tumor cells in metastatic and clinically localized urothelial cancer. Urology 2011 AUG 1, 2011 [epub ahead of print] PMID 21813167,

Flaig TW, Theodorescu D. Expert Editorials: Progress and Challenges in Personalized Medicine in Bladder Cancer. 2012 Genitourinary Cancer Symposium – Daily News. February 2, 2012, Genitourinary Cancers Symposium, San Francisco, CA.

Chi KN, Drake CG, Flaig TW. Systemic therapy for castration-resistant prostate cancer: Novel agents and new standards. ASCO Education Book. 2011: 163-9.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. PubMed PMID: 28982750

Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glodé LM, Flaig TW. A rare case of metastatic renal epithelioid angiomyolipoma. Oncology. 2011; 25(9): 832-8. PMID: 21936445

Flaig TW, Salzmann-Sullivan M, Su LJ, Zhang Z, Joshi M, Gijón MA, Kim J, Arcaroli JJ, Van Bokhoven A, Lucia MS, La Rosa FG, Schlaepfer IR. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. 2017 Aug 22;8(34):56051-56065. PubMed PMID: 28915573

Flaig TW, Theodorescu D. Bladder Cancer in 2011: The Dawn of Personalized Medicine. Nature Reviews Urology. 2012; 9(2): 65-6.

Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C, DeGraff D, Liao JC, Taylor JA 3rd. Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer. 2017 Jul 27;3(3):211-223. PubMed PMID: 28824949

Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. Bladder Cancer. 2017 Jul 27;3(3):201-210. PubMed PMID: 28824948

Crawford ED, Flaig TW. Advanced prostate cancer: Drug sequencing and novel therapeutic approaches. Oncology. 2012; 26(1): 70-77.

Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 Mar 1;28(3):668. PubMed PMID: 28426121

Clemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urologic Oncology. 2013; 31(2):198-204. PMID 21795073

Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM Jr. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Nov 9;3(11):e170231. PubMed PMID: 28358937

Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Investigational New Drugs. 2013; 31(1):115-25. PMID:22415798

Kessler E, Flaig TW. Optimal Management of Recurrent Prostate Cancer in Older Patients. Drugs & Aging. Drugs Aging. 2012; 29(11):871-83. PMID: 23135826

Yang X, Bemis L, Su L-J, Gao D, Flaig TW. miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. BioResearch Open Access. 2012, 1(2): 55-62. PMID:23514806

Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. PubMed PMID: 28344102

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 2012; 367(13):1187-97. PMID: 22894553

Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW. Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib. Clinical Genitourinary Cancer. 2012; 10(4): 225-31. PMID: 23017335

Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today. 2012, 48(10): 633-644.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017 Jun 1;28(6):1339-1345. PubMed PMID: 28327953

Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Jun;35(6):438-446. PubMed PMID: 28214281

Yang X, Kessler E, Su, L Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li C, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer. Clinical Cancer Research. 2012; 19(1): 148-57. PMID:23172881

Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database. Clin Genitourin Cancer. 2017 Apr;15(2):273-279.e1. PubMed PMID: 27876504

Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol. 2012; 10(1): 41-51. PMID:23183631

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine. 2013;368(2): 138-48. PMID:23228172

Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. Urology. 2017 Apr;102:7-16. PubMed PMID: 27769917

Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW. Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma. Dermatol Surg. 2013 Mar 6. [Epub ahead of print] PMID:23464361

Lam ET, Flaig TW. Prostate cancer: Celecoxib trampled in the STAMPEDE trial. Nature Review Urology. 2012 9(7): 358-60.

Flaig TW, Theodorescu D. Words of Wisdom - Re: Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. European Urology. 2012 62(1):183-4.

de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 Apr;71(4):656-664. PubMed PMID: 27402060

Bernard B, Flaig TW. Point-Prostate Cancer Genomic Analysis: Routine or Research Only?. Oncology (Williston Park). 2018 Dec 17;32(12):607-9. PubMed PMID: 30632132

Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 Dec;17(4):1103-1108. PubMed PMID: 30289005

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. PubMed PMID: 30181416

Castro-Alonso FJ, Dominguez-Pineda J, Rosales-Sotomayor G, Flaig TW, Bourlon MT. Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors. Oncology (Williston Park). 2018 May 15;32(5):243-6. PubMed PMID: 29847858

Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM. Contribution of bladder cancer pathology assessment in planning clinical trials. Urol Oncol. 2018 Feb 1. [Epub ahead of print] PubMed PMID: 29395955

Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018;7:307. PubMed PMID: 29568504

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 May 20;36(15):1498-1504. PubMed PMID: 29624463

Flaig TW. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma. J Natl Compr Canc Netw. 2018 May;16(5S):636-638. PubMed PMID: 29784744

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2018 Nov 1;29(11):2269. PubMed PMID: 29390043

Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 Sep;24(9):1149-e807. PubMed PMID: 31152080

Flaig TW. NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):591-593. PubMed PMID: 31117036

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 May 1;37(13):1051-1061. PubMed PMID: 30817251

Cho SK, Su LJ, Mao C, Wolenski CD, Flaig TW, Park W. Multifunctional nanoclusters of NaYF(4):Yb(3 ),Er(3 ) upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:784-792. PubMed PMID: 30678969

Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, Ormond DR, Lam ET, Kavanagh BD, Flaig TW. Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clin Genitourin Cancer. 2020 Aug 22. [Epub ahead of print] PubMed PMID: 33069585

Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 Nov;22(11):1541-1559. PubMed PMID: 34600602

Nordeen SK, Su LJ, Osborne GA, Hayman PM, Orlicky DJ, Wessells VM, van Bokhoven A, Flaig TW. Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. Life (Basel). 2021 Aug 27;11(9). PubMed PMID: 34575033

Boxley P, Plets M, Flaig TW. Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. Bladder Cancer. 2020 Jun 11;6(2):123-129. PubMed PMID: 32793789

Petrylak DP, Ratta R, Gafanov R, Facchini G, Piulats JM, Kramer G, Flaig TW, Chandana SR, Li B, Burgents J, Fizazi K. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021 Sep;17(25):3291-3299. PubMed PMID: 34098744

Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 Aug 1;39(22):2486-2496. PubMed PMID: 33989025

Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 Oct;78(4):603-614. PubMed PMID: 32336645

Yu EY, Hancock ML, Aronson W, Flaig T, Belkoff L, Tutrone R, Taylor R, Hardigan PC, Getzenberg RH. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020 Dec;18(6):436-443. PubMed PMID: 32321673

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020 May;17(5):259-270. PubMed PMID: 32235944

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. PubMed PMID: 32135513

Rodrigues Pessoa R, Mueller AC, Boxley P, Flaig TW, Piper C, Konety B, Yu JB, Gershman B, Kukreja J, Kim SP. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urol Oncol. 2021 Nov;39(11):786.e1-786.e8. PubMed PMID: 33846085

Amirault M, Choo S, Waxweiler T, Weisdack SD, Breaker K, Flaig TW, Lam ET. Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. Cancer Treat Res Commun. 2021;27:100367. PubMed PMID: 33839514

Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol. 2020 Apr 1;38(10):1041-1049. PubMed PMID: 32031899

Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 Dec;39(12):832.e9-832.e15. PubMed PMID: 33820697

Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 Apr 20;39(12):1371-1382. PubMed PMID: 33617303

Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 May 1;27(9):2435-2441. PubMed PMID: 33568346

Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, Ormond DR, Lam ET, Kavanagh BD, Flaig TW. Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clin Genitourin Cancer. 2021 Jun;19(3):217-222.e1. PubMed PMID: 33069585

Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM. Contribution of bladder cancer pathology assessment in planning clinical trials. Urol Oncol. 2021 Oct;39(10):713-719. PubMed PMID: 29395955

Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2022 Nov 19. [Epub ahead of print] PubMed PMID: 36402814

Necchi A, Joshi M, Bangs R, Makaroff L, Grivas P, Kamat AM, Kassouf W, Raggi D, Marandino L, Krupski T, Flaig TW, Spiess PE. Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clin Genitourin Cancer. 2022 Oct 13. [Epub ahead of print] PubMed PMID: 36344399

Bourlon MT, Verduzco-Aguirre H, Molina E, Meyer E, Kessler E, Kim SP, Spiess PE, Flaig T. Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis. Front Oncol. 2022;12:926692. PubMed PMID: 35847850

Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. PubMed PMID: 35948037

Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023 Jan 1;41(1):22-31. PubMed PMID: 36041086

Mazhindu T, Ndlovu N, Borok MZ, Meki S, Nyamhunga A, Havranek EP, Kessler ER, Campbell TB, Flaig TW. Metabolic and cardiovascular disease risk for Zimbabwean men with prostate cancer receiving long-term androgen deprivation therapy. Res Sq. 2023 Dec 12. PubMed PMID: 38168443

Wiesen B, Atwell M, Leavitt C, Clark N, Kessler E, Lam E, Flaig T, Kukreja J, Kim S, Maroni P, Cost NG. Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncol Pract. 2023 Dec 21;:OP2300580. [Epub ahead of print] PubMed PMID: 38127812

Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. Future Oncol. 2023 Nov 23. [Epub ahead of print] PubMed PMID: 37994649

Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2023 Nov 15. [Epub ahead of print] PubMed PMID: 37966367

Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr, Lerner SP. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 Sep;84(3):341-347. PubMed PMID: 37414705

Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 Jun;3(6):1004-1012. PubMed PMID: 37377613

O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. PubMed PMID: 37369081

Candelario NC, Molina E, Bourlon MT, Kim SP, Kessler ER, Spiess PE, Flaig TW. Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database. Urol Oncol. 2023 Aug;41(8):359.e15-359.e23. PubMed PMID: 37344326

Castro-Alonso FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, Bourlon MT. Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma. Oncology (Williston Park). 2023 Jun 12;37(6):256-261. PubMed PMID: 37343207

Warrick JI, Al-Ahmadie H, Berman DM, Black PC, Flaig TW, Höglund M, Bubendorf L, van der Kwast TH, Cheng L. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility. Am J Surg Pathol. 2024 Jan 1;48(1):e32-e42. PubMed PMID: 37199442

Lu YT, Plets M, Morrison G, Cunha AT, Cen SY, Rhie SK, Siegmund KD, Daneshmand S, Quinn DI, Meeks JJ, Lerner SP, Petrylak DP, McConkey D, Flaig TW, Thompson IM Jr, Goldkorn A. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 Oct;6(5):516-524. PubMed PMID: 37087309

Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):188-193. PubMed PMID: 36402814

Necchi A, Joshi M, Bangs R, Makaroff L, Grivas P, Kamat AM, Kassouf W, Raggi D, Marandino L, Krupski T, Flaig TW, Spiess PE. Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clin Genitourin Cancer. 2023 Apr;21(2):301-308. PubMed PMID: 36344399

Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023 Jan 1;41(1):22-31. PubMed PMID: 36041086

Professor, Medicine-Medical Oncology

Medical School

Undergraduate School

Internship

Residency

Fellowships

Languages

Department

Professional Titles

Publications

Practice Locations

Specialty Information

School of Medicine

CU Anschutz

Fitzsimons Building